Elfi Vergaelen1, Carmen Schiweck2, Kristof Van Steeland2, Jacqueline Counotte3, Wim Veling4, Ann Swillen5, Hemmo Drexhage6, Stephan Claes2. 1. University Psychiatric Center KU Leuven, University Hospital Leuven, Leuven, Belgium; Center for Human Genetics, University Hospital Leuven, Leuven, Belgium. Electronic address: elfi.vergaelen@uzleuven.be. 2. University Psychiatric Center KU Leuven, University Hospital Leuven, Leuven, Belgium. 3. Parnassia Psychiatric Institute, The Hague, The Netherlands. 4. University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, The Netherlands. 5. Center for Human Genetics, University Hospital Leuven, Leuven, Belgium; Department of Human Genetics, KU Leuven, Leuven, Belgium. 6. Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.
Abstract
BACKGROUND: A growing body of evidence supports a role for immune alterations in Schizophrenia Spectrum Disorders (SSD). A high prevalence (25-40%) of SSD has been found in patients with 22q11.2 deletion syndrome (22q11.2DS), which is known for T-cell deficits due to thymus hypoplasia. This study is the first to explore the association between the T-cell subsets and psychotic symptoms in adults with 22q11.2DS. METHODS: 34 individuals (aged 19-38 yrs.) with 22q11.2DS and 34 healthy age- and gender matched control individuals were included. FACS analysis of the blood samples was performed to define T-cell subsets. Ultra-high risk for psychosis or diagnosis of SSD was determined based on CAARMS interviews and DSM-5 criteria for SSD. Positive psychotic symptom severity was measured based on the PANSS positive symptoms subscale. RESULTS: A partial T-cell immune deficiency in 22q11.2DS patients was confirmed by significantly reduced percentages of circulating T and T-helper cells. Significantly higher percentages of inflammatory Th1, Th17, and memory T-helper cells were found in adults with 22q11.2DS. Most importantly an increased Th17 percentage was found in adults with psychotic symptoms as compared to non-psychotic adults with 22q11.2DS, and Th17 percentage were related to the presence of positive psychotic symptoms. CONCLUSIONS: Given the literature on the role of T cells and in particular of Th17 cells and IL-17 in hippocampus development, cognition and behavior, these results support the hypothesis for a role of Th17 cells in the development and/or regulation of psychotic symptoms in 22q11.2DS. This pilot study underlines the importance to further study the role of T-cell defects and of Th17 cells in the development of psychiatric symptoms. It also supports the possibility to use 22q11.2DS as a model to study T-cell involvement in the development of SSD.
BACKGROUND: A growing body of evidence supports a role for immune alterations in Schizophrenia Spectrum Disorders (SSD). A high prevalence (25-40%) of SSD has been found in patients with 22q11.2 deletion syndrome (22q11.2DS), which is known for T-cell deficits due to thymus hypoplasia. This study is the first to explore the association between the T-cell subsets and psychotic symptoms in adults with 22q11.2DS. METHODS: 34 individuals (aged 19-38 yrs.) with 22q11.2DS and 34 healthy age- and gender matched control individuals were included. FACS analysis of the blood samples was performed to define T-cell subsets. Ultra-high risk for psychosis or diagnosis of SSD was determined based on CAARMS interviews and DSM-5 criteria for SSD. Positive psychotic symptom severity was measured based on the PANSS positive symptoms subscale. RESULTS: A partial T-cell immune deficiency in 22q11.2DS patients was confirmed by significantly reduced percentages of circulating T and T-helper cells. Significantly higher percentages of inflammatory Th1, Th17, and memory T-helper cells were found in adults with 22q11.2DS. Most importantly an increased Th17 percentage was found in adults with psychotic symptoms as compared to non-psychotic adults with 22q11.2DS, and Th17 percentage were related to the presence of positive psychotic symptoms. CONCLUSIONS: Given the literature on the role of T cells and in particular of Th17 cells and IL-17 in hippocampus development, cognition and behavior, these results support the hypothesis for a role of Th17 cells in the development and/or regulation of psychotic symptoms in 22q11.2DS. This pilot study underlines the importance to further study the role of T-cell defects and of Th17 cells in the development of psychiatric symptoms. It also supports the possibility to use 22q11.2DS as a model to study T-cell involvement in the development of SSD.
Authors: Maiara Zeni-Graiff; Lucas B Rizzo; Rodrigo B Mansur; Pawan K Maurya; Sumit Sethi; Graccielle R Cunha; Elson Asevedo; Pedro Pan; André Zugman; Ana S Yamagata; Cinthia Higuchi; Rodrigo A Bressan; Ary Gadelha; Elisa Brietzke Journal: Schizophr Res Date: 2016-08-08 Impact factor: 4.939
Authors: U H Frommberger; J Bauer; P Haselbauer; A Fräulin; D Riemann; M Berger Journal: Eur Arch Psychiatry Clin Neurosci Date: 1997 Impact factor: 5.270
Authors: Gloria B Choi; Yeong S Yim; Helen Wong; Sangdoo Kim; Hyunju Kim; Sangwon V Kim; Charles A Hoeffer; Dan R Littman; Jun R Huh Journal: Science Date: 2016-01-28 Impact factor: 47.728
Authors: Maude Schneider; Martin Debbané; Anne S Bassett; Eva W C Chow; Wai Lun Alan Fung; Marianne van den Bree; Michael Owen; Kieran C Murphy; Maria Niarchou; Wendy R Kates; Kevin M Antshel; Wanda Fremont; Donna M McDonald-McGinn; Raquel E Gur; Elaine H Zackai; Jacob Vorstman; Sasja N Duijff; Petra W J Klaassen; Ann Swillen; Doron Gothelf; Tamar Green; Abraham Weizman; Therese Van Amelsvoort; Laurens Evers; Erik Boot; Vandana Shashi; Stephen R Hooper; Carrie E Bearden; Maria Jalbrzikowski; Marco Armando; Stefano Vicari; Declan G Murphy; Opal Ousley; Linda E Campbell; Tony J Simon; Stephan Eliez Journal: Am J Psychiatry Date: 2014-06 Impact factor: 18.112
Authors: Milica M Borovcanin; Slavica Minic Janicijevic; Ivan P Jovanovic; Nevena M Gajovic; Milena M Jurisevic; Nebojsa N Arsenijevic Journal: Diagnostics (Basel) Date: 2020-11-10
Authors: Jenny Lingman Framme; Christina Lundqvist; Anna-Carin Lundell; Pauline A van Schouwenburg; Andri L Lemarquis; Karolina Thörn; Susanne Lindgren; Judith Gudmundsdottir; Vanja Lundberg; Sofie Degerman; Rolf H Zetterström; Stephan Borte; Lennart Hammarström; Esbjörn Telemo; Magnus Hultdin; Mirjam van der Burg; Anders Fasth; Sólveig Oskarsdóttir; Olov Ekwall Journal: J Clin Immunol Date: 2022-01-26 Impact factor: 8.542